Nuvessa (Metronidazole) Patent Expiration, LOE Window & CMS Spending

Nuvessa (Metronidazole) by Alembic Therapeutics: FDA Orange Book LOE 2032-06-28, 7 AB generics, $4.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlembic Therapeutics
FDA Application & PathwayN205223 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-06-28
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$4.5M
2024 Medicare Part D Spend$130K
2024 Medicaid Spend$4.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel